Psoriasis – Landscape & Forecast – Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is increasingly being challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been phenomenal, raising an alarm for other approved biologics. The anticipated approvals of bimekizumab (in the United States), an IL-17 inhibitor; deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor; and the nonsteroidal topical agents roflumilast and tapinarof will further increase the number of psoriasis treatments and make the market even more competitive.

Questions answered:

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq/Lumicef) and the emerging IL-17 A/F dual inhibitor bimekizumab, and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of newer IL-23 inhibitors (Ilumya and Skyrizi) on TNF-alpha inhibitors, anti-IL-17s, and the first-in-class IL-23 inhibitor, Tremfya? How are/will these newer agents fare in the competitive psoriasis market?
  • How will the oral TYK2 inhibitor deucravacitinib affect apremilast’s (Amgen’s Otezla) patient share, and how will the two agents compare on efficacy and safety attributes?
  • What will be the future of the novel topical therapies roflumilast, a PDE-4 inhibitor, and tapinarof, a TAMA?

Content highlights:

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 31 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.

Emerging therapies: Phase III/PR: 6 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.

Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2030, segmented by brands/generics and epidemiological subpopulations.

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement:

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Psoriasis - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
      • Q3 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Psoriasis Drug Classes in 2020
          • Market Share of Psoriasis Drug Classes in 2030
          • Psoriasis SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Constraining the Market for Psoriasis?
          • Major-Market Sales of Select Drug Classes in Psoriasis: 2020-2030
          • Annual Sales of Biologics and Key Oral Agents in Psoriasis: 2020-2030
        • Drug-Class-Specific Trends
          • Patient Share of TNF-Alpha Inhibitors in Moderate to Severe Psoriasis by Country: 2020-2030
          • Brand and Biosimilar Patient Share for TNF-Alpha Inhibitors in Psoriasis: 2020-2030
          • Major-Market Sales of TNF-Alpha Inhibitors and IL-12/23 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
          • Major-Market Patient Share of TNF-Alpha Inhibitors, IL-12/23 Inhibitors, and IL-17 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
          • Major-Market Patient Share of TNF-Alpha Inhibitors, IL-12/23 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
          • TYK2 Inhibitors
          • Major-Market Sales of Biologics and Novel Oral Therapies in Moderate to Severe Psoriasis: 2020-2030
          • Major-Market Patient Share of Traditional Oral Drug Classes, PDE-4 Inhibitors, A3 Adenosine Receptor Agonists, and TYK2 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
          • Major-Market Sales of Traditional Oral Drug Classes, PDE4 Inhibitors, A3 Adenosine Receptor Agonists, and TYK2 Inhibitors in Moderate to Severe Psoriasis: 2020-2030
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Etiology
          • Risk Factors
        • Pathophysiology
          • Clinical Features
          • Typical Locations of Psoriasis Lesions
          • Classification of Psoriasis Vulgaris by Phenotype
          • Clinical Forms of Psoriasis
        • Key Pathways and Drug Targets
          • Pathogenesis of Psoriasis and Therapeutic Targets
          • Pathogenesis and Drug Targets
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Symptomatic Prevalence of Psoriasis
            • Number of Diagnosed Symptomatic Prevalent Cases of Psoriasis in the Major Pharmaceutical Markets:u00a02020-2030 (thousands)
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Symptomatic Prevalent Psoriasis by Severity
            • Sources Used for Drug-Treated Cases of Psoriasis
            • Number of Diagnosed and Drug-Treated Prevalent Cases of Mild Psoriasis in the Major Pharmaceutical Markets: 2020-2030 (thousands)
            • Number of Diagnosed and Drug-Treated Prevalent Cases of Moderate to Severe Psoriasis in the Major Pharmaceutical Markets: 2020-2030 (thousands)
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Psoriasis
              • Key Physician Insights on Clinical Endpoints
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for Psoriasis
              • Current Therapies Used for Mild Psoriasis
              • Current Therapies Used for Moderate to Severe Psoriasis
              • Market Events Impacting the Use of Key Current Therapies in Psoriasis
              • Advantages and Disadvantages of Etanercept
              • Expert Insight: Etanercept
              • Advantages and Disadvantages of Infliximab
              • Expert Insight: Infliximab
              • Advantages and Disadvantages of Adalimumab
              • Expert Insight: Adalimumab
              • Certolizumab Pegol
              • Advantages and Disadvantages of Certolizumab Pegol
              • Expert Insight: Certolizumab Pegol
              • Advantages and Disadvantages of Ustekinumab
              • Expert Insight: Ustekinumab
              • Advantages and Disadvantages of Secukinumab
              • Expert Insight: Secukinumab
              • Ongoing Clinical Development of Cosentyx
              • Key Ongoing Clinical Trials of Cosentyx in the Treatment of New-Onset Moderate to Severe Psoriasis
              • Advantages and Disadvantages of Ixekizumab
              • Expert Insight: Ixekizumab
              • Advantages and Disadvantages of Brodalumab
              • Expert Insight: Brodalumab
              • Advantages and Disadvantages of Guselkumab
              • Expert Insight: Guselkumab
              • Advantages and Disadvantages of Tildrakizumab
              • Expert Insight: Tildrakizumab
              • Advantages and Disadvantages of Risankizumab
              • Expert Insight: Risankizumab
              • Advantages and Disadvantages of Apremilast
              • Expert Insight: Apremilast
              • Advantages and Disadvantages of Conventional Systemic Therapies
              • Expert Insight: Conventional Systemic Therapies
              • Advantages and Disadvantages of Topical Therapies
              • Expert Insight: Topical Therapies
            • Medical Practice
              • Overview
              • Drug Selection
              • Factors Influencing Drug Selection in Moderate to Severe Psoriasis
              • Preferred Treatment of Psoriasis by Disease Location and Comorbidities
              • Region-Specific Treatment Practices
              • Treatment Decision Tree for Psoriasis: United States
              • Treatment Decision Tree for Psoriasis: France
              • Treatment Decision Tree for Psoriasis: Germany
              • Treatment Decision Tree for Psoriasis: Italy
              • Treatment Decision Tree for Psoriasis: Spain
              • Treatment Decision Tree for Psoriasis: United Kingdom
              • Treatment Decision Tree for Psoriasis: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Psoriasis
            • Top Unmet Needs in Psoriasis: Current and Future Attainment
            • Expert Insight: Unmet Needs in Moderate to Severe Psoriasis
          • Drug Pipeline
            • Pipeline
            • Regulatory Milestones
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Therapies in Late-Phase Development for Psoriasis
                • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Psoriasis
                • Bimekizumab Profile
                • Key Ongoing Clinical Trials of Bimekizumab in the Treatment of Psoriasis
                • Analysis of the Clinical Development Program for Bimekizumab
                • Expert Insight: Bimekizumab
                • Expectations for Launch and Sales Opportunity of Bimekizumab in Psoriasis
                • Piclidenoson Profile
                • Analysis of the Clinical Development Program for Piclidenoson
                • Expert Insight: Piclidenoson
                • Expectations for Launch and Sales Opportunity of Piclidenoson in Psoriasis
                • Likely Uses of Piclidenoson in the Treatment of Psoriasis
                • BMS-986165 Profile
                • Key Ongoing Clinical Trials of BMS-986165 in the Treatment of Psoriasis
                • Analysis of the Clinical Development Program for BMS-986165
                • Expert Insight: BMS-986165
                • Expectations for Launch and Sales Opportunity of BMS-986165 in Psoriasis
                • Likely Uses of BMS-986165 in the Treatment of Psoriasis
                • Pefcalcitol Profile
                • Analysis of the Clinical Development Program for Pefcalcitol
                • Expectations for Launch and Sales Opportunity of Pefcalcitol in Psoriasis
                • Tapinarof Profile
                • Analysis of the Clinical Development Program for Tapinarof
                • Expert Insights: Tapinarof
                • Expectations for Launch and Sales Opportunity of Tapinarof in Psoriasis
                • Roflumilast Profile
                • Key Ongoing Clinical Trials of Roflumilast in the Treatment of Psoriasis
                • Analysis of the Clinical Development Program for Roflumilast
                • Expert Insight: Roflumilast
                • Expectations for Launch and Sales Opportunity of Roflumilast in Psoriasis
              • Early-Phase Pipeline Analysis
                • Select Compounds in Early-Phase Development for Psoriasis
              • Key Discontinuations and Failures in Psoriasis
              • Access & Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in Psoriasis: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in Psoriasis: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in Psoriasis: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • Psoriasis Bibliography

            launch Related Market Assessment Reports